After a decade dissecting the molecular heterogeneity of HER2-positive breast cancer,5,17,21,22 we and others have elucidated the 4 main biological drivers of clinical behaviour, namely immune infiltration, luminal differentiation, tumour cell proliferation and HER2 amplicon expression. This evidence concerns the gene ERBB2 and neoplasm.